Antigravity Announces Newest Innovation at IFA, Expanding Creative Possibilities

4.9.2026 09:00:00 CEST | news aktuell GmbH | Press release

Share

Berlin, Germany - Today at IFA, Antigravity, an aerial technology brand incubated by Insta360, announced its latest innovation, the Antigravity Cellular Module, which is designed to give creators greater freedom and reliability in flight.

Antigravity IFA 2026
Antigravity IFA 2026

The Cellulare Module enhances A1's transmission reliability by adding a 4G connection. Working alongside the A1’s OmniLink 360 system, the module provides an additional connection when the primary transmission link encounters interference or obstruction. In complex urban environments, it helps maintain a stable video connection while supporting smoother transmission over longer distances. The module can be mounted directly onto the drone and Vision Goggles and features an integrated eSIM for convenient connectivity while traveling. The Antigravity Cellular Module will be available by the end of September 2026.

At IFA 2026, Antigravity will give attendees the chance to experience the award-winning Antigravity A1 for themselves. Visitors can head to the on-site flight change and try the intuitive Point-to-Fly controls, simply aiming the Grip Motion Controller in their desired direction and setting the drone in motion. They can also put on the Vision Goggles to immerse themselves in a 360 flight, soaring over the landscape below. Throughout the event, Antigravity will host activities, giveaways, and workshops led by creators and professional pilots.

IFA 2026

Date: September 4 - 8

Booth Location: Messe Berlin Hall 20, Booth 120

Press Contact
Antigravity PR Team
pr@antigravity.tech

About Antigravity

Incubated by Insta360 in collaboration with third parties, Antigravity uses the latest 360 technology to build powerful drones with immersive flight and intuitive controls. The company released the world's first 8K 360 drone, Antigravity A1, in late 2025 as the first step in its mission to inspire a new generation of aerial explorers and storytellers.

Images

Antigravity IFA 2026
Antigravity IFA 2026
Download

About news aktuell GmbH

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release

New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye